Phase 2 Clinical Results: Chikungunya Vaccine Based on Measles Vector (MV-CHIK) Induces Humoral and Cellular Responses in the Presence of Pre-Existing Anti Measles Immunity

International Journal of Infectious Diseases - Netherlands
doi 10.1016/j.ijid.2018.11.291